Incyte (WBO:INCY) Buildings And Improvements : €536 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Incyte Buildings And Improvements?

Incyte's quarterly buildings and improvements increased from Jun. 2023 (€528 Mil) to Sep. 2023 (€533 Mil) and increased from Sep. 2023 (€533 Mil) to Dec. 2023 (€536 Mil).

Incyte's annual buildings and improvements increased from Dec. 2021 (€384 Mil) to Dec. 2022 (€533 Mil) and increased from Dec. 2022 (€533 Mil) to Dec. 2023 (€536 Mil).

Incyte Buildings And Improvements Historical Data

The historical data trend for Incyte's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Buildings And Improvements Chart

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buildings And Improvements

Get a 7-Day Free Trial

187.46

195.67

384.37

532.58

536.22

Incyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Buildings And Improvements	Get a 7-Day Free Trial															532.58	530.38	527.67	532.90	536.22

Incyte Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Incyte (WBO:INCY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (WBO:INCY) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

INCY:USA 1INCY:Italy ICY:Germany I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.